Literature DB >> 25039683

Nonagenarians undergoing cardiac surgery.

John P Davis1, Damien J LaPar, Ivan K Crosby, John A Kern, Christine L Lau, Irving L Kron, Gorav Ailawadi.   

Abstract

BACKGROUND: As life expectancy continues to rise and cardiac surgical outcomes improve, the number of nonagenarian (age > 90 years) patients undergoing cardiac operations is increasing. However, little has been reported on cardiac surgical outcomes in this select patient population. The purpose of this study was to examine current cardiac surgical outcomes for nonagenarian patients and determine the impact of extreme age on contemporary risk calculations. STUDY
DESIGN: From 2002 to 20012, 61,303 patients underwent cardiac operations as reported in a statewide Society of Thoracic Surgeons (STS) Adult Cardiac Surgery database, including 108 nonagenarians. Patient and operative factors, including STS Predicted Risk of Mortality (PROM), were analyzed in order to compare to estimated risk measures.
RESULTS: Nonagenarian patients (median age = 92 years) had a high prevalence of preoperative cerebrovascular disease (23.1% [25/108]) and arrhythmia (55.6% [60/108]). Isolated coronary artery bypass grafting (CABG) (39.8% [43/108]) was the most common operation performed within this cohort, followed by aortic valve replacement (AVR: 35.2% [38/108], AVR + CABG 23.1% [25/108]) operations. Overall nonagenarian mortality was 13% [14/108] and was greatest for AVR. Among nonagenarians with calculated STS PROM, observed to expected (O:E) ratios for mortality ranged from 1.45 to 2.65 annually over the study period.
CONCLUSIONS: Nonagenarian patients represent a high-risk, elderly patient population with higher morbidity than predicted. Mortality is greatest following aortic valve operations. These results suggest that current risk calculations may underestimate the impact of extreme age on perioperative mortality.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25039683     DOI: 10.1111/jocs.12391

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  6 in total

1.  Transcatheter aortic valve replacement in nonagenarians: early and intermediate outcome from the OBSERVANT study and meta-analysis of the literature.

Authors:  Fausto Biancari; Paola D'Errigo; Stefano Rosato; Marek Pol; Corrado Tamburino; Marco Ranucci; Fulvia Seccareccia
Journal:  Heart Vessels       Date:  2016-06-01       Impact factor: 2.037

2.  Perioperative considerations in nonagenarians.

Authors:  Maria E Tecos; Brittany S Kern; Nathan A Foje; Marilyn L Leif; Mitchell Schmidt; Allie Steinberger; Adam Bajinting; Keely L Buesing
Journal:  Surg Open Sci       Date:  2020-04-26

3.  Performance of the EuroSCORE II and the STS score for cardiac surgery in octogenarians.

Authors:  Hüseyin Kuplay; Sevinç Bayer Erdoğan; Murat Baştopçu; Eren Karpuzoğlu; Halit Er
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

4.  Acute kidney injury among nonagenarians in Jordan: a retrospective case-control study.

Authors:  Sameeha A Alshelleh; Ashraf O Oweis; Karem H Alzoubi
Journal:  Int J Nephrol Renovasc Dis       Date:  2018-11-30

5.  Modern Cardiac Surgical Outcomes in Nonagenarians: A Multicentre Retrospective Observational Study.

Authors:  Laurence Weinberg; Dominic Walpole; Dong Kyu Lee; Michael D'Silva; Jian Wen Chan; Lachlan Fraser Miles; Bradly Carp; Adam Wells; Tuck Seng Ngun; Siven Seevanayagam; George Matalanis; Ziauddin Ansari; Rinaldo Bellomo; Michael Yii
Journal:  Front Cardiovasc Med       Date:  2022-07-14

6.  The early and long-term outcomes of coronary artery bypass grafting added to aortic valve replacement compared to isolated aortic valve replacement in elderly patients: a systematic review and meta-analysis.

Authors:  Stefano D'Alessandro; Domenico Tuttolomondo; Gurmeet Singh; Daniel Hernandez-Vaquero; Claudia Pattuzzi; Alan Gallingani; Francesco Maestri; Francesco Nicolini; Francesco Formica
Journal:  Heart Vessels       Date:  2022-05-09       Impact factor: 1.814

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.